Direct-acting Antivirals Treat HIV/HCV Coinfection in Real-world Study
Twelve-week viral eradication rates were high in patients coinfected with HCV and HIV, particularly in those without advanced cirrhosis.
Advanced Cirrhosis Patients Respond to DAAs in Real-world Study
High sustained virologic response rates were seen among patients with decompensated cirrhosis in European compassionate care cohort.
DAA Combination Confirmed Highly Effective Against HCV in Real-world Setting
Sustained virologic response was seen in 99% of subjects, reflecting rates seen in pre-registration studies. Adverse events were mild.
DAAs Cost-effective in HCV Patients with Advanced Fibrosis
A modeling study compared health benefits and costs of all currently licensed treatments, both singly and in sequential therapy of up to 3 lines.
Antivirals Safe for HCV After Kidney Transplant
With new direct-acting antiviral agents, a rapid virological response was observed in a majority of patients.
Partial Antiviral Courses for HCV Get Response
SVR12 rates are high with sofosbuvir-based treatment regimens even when patients receive less than a full course of treatment.
Hep C Spread in North America: When and How did it Start?
Timing of the rise of hep C in North America is a puzzle. In this Medical News Minute, Dr Bobby Lazzara toplines results of a new study that offer clarity.
By clicking Accept, you agree to become a member of the UBM Medica Community.